Crisantaspase
B-Cell Acute Lymphoblastic Leukemia
City of Hope Medical Centerprotein_peptidePhase 3Active
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 89/ 100
Competitive context
135 Active assets in the B-Cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide University of Washington | Phase 3 | BBB |
Vincristine Sulfate City of Hope Medical Center | Phase 3 | BB |
Dasatinib National Cancer Institute (NCI) | Phase 3 | BB |
Pegaspargase National Cancer Institute (NCI) | Phase 3 | BB |
Nivestim University of Washington | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Crisantaspase is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →